American Century Companies Inc. Grows Holdings in Solventum Co. (NYSE:SOLV)

American Century Companies Inc. boosted its holdings in shares of Solventum Co. (NYSE:SOLV) by 43.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 146,608 shares of the company’s stock after purchasing an additional 44,251 shares during the period. American Century Companies Inc.’s holdings in Solventum were worth $9,685,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Worldquant Millennium Advisors LLC lifted its holdings in shares of Solventum by 373.6% during the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after purchasing an additional 37,600 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of Solventum by 24.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after acquiring an additional 9,333 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Solventum by 37.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after acquiring an additional 32,051 shares during the period. State Street Corp boosted its holdings in shares of Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares in the last quarter. Finally, Forsta AP Fonden acquired a new position in shares of Solventum during the fourth quarter worth about $1,876,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group lifted their price objective on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Mizuho lifted their price target on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Bank of America upped their price objective on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. Wells Fargo & Company raised their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Finally, Piper Sandler upped their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Stock Up 0.3 %

Solventum stock opened at $76.54 on Thursday. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The firm has a market capitalization of $13.24 billion and a price-to-earnings ratio of 27.83. The stock’s fifty day moving average is $75.66 and its two-hundred day moving average is $72.00. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.